Stockreport

Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF Data from Phase 3 clinical trial demonstrate statistically significant effect achieved at all pre-specified primary endpointsThe Company intends to submit an sNDA to exp [Read more]